UnknownNot applicableNCT05821192

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Studying Angioimmunoblastic T-cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ou Bai, MD/PHD
Principal Investigator
Ou Bai, doctor
The First Hospital of Jilin University
Intervention
Rituximab(drug)
Enrollment
34 enrolled
Eligibility
18-70 years · All sexes
Timeline
2023 – 2024

Study locations (1)

Collaborators

Second Hospital of Jilin University · China-Japan Union Hospital, Jilin University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05821192 on ClinicalTrials.gov

Other trials for Angioimmunoblastic T-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Angioimmunoblastic T-cell lymphoma →

← Back to all trials